PRIVATE PATENTS AND PUBLIC HEALTH
private-patents-and-public-health
private-patents-and-public-health
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>PRIVATE</strong> <strong>PATENTS</strong> <strong>AND</strong> <strong>PUBLIC</strong> <strong>HEALTH</strong><br />
IP/C/25, https://www.wto.org/<br />
english/tratop_e/trips_e/art66_1_e.<br />
htm<br />
62 Sangeeta Shashikant, “Unconditional<br />
17-year exemption from<br />
pharmaceuticals patents agreed,”<br />
Third World Network Info Service on<br />
Intellectual Property Issues, 3 November<br />
2015, http://twn.my/title2/<br />
intellectual_property/info.<br />
service/2015/ip151101.htm<br />
63 Carlos Correa, “Implications of the<br />
Doha Declaration on the TRIPS<br />
Agreement and Public Health,”<br />
Health Economics and Drugs Series, No.<br />
12. Geneva, Switzerland: World<br />
Health Organization, June 2002,<br />
http://apps.who.int/medicinedocs/<br />
en/d/Js2301e/<br />
64 Communication from the European<br />
Communities and their member<br />
States to the World Trade<br />
Organization Council for Trade-<br />
Related Aspects of Intellectual<br />
Property Rights, “Concept Paper<br />
relating to paragraph 6 of the Doha<br />
Declaration on the TRIPS Agreement<br />
and Public Health,” IP/C/W/339, 4<br />
March 2002, https://docs.wto.org/<br />
dol2fe/Pages/FE_Search/<br />
DDFDocuments/70701/Q/IP/C/W339.<br />
pdf<br />
65 Médecins Sans Frontières Campaign<br />
for Access to Essential Medicines,<br />
“Why Article 30 will work. Why<br />
Article 31 will not,” 24 June 2002,<br />
http://www.msfaccess.org/content/<br />
why-article-30-will-work-whyarticle-31-will-not<br />
66 Letter from the Consumer Project on<br />
Technology, Oxfam, Médecins Sans<br />
Frontières, and Health Action<br />
International to WTO delegates<br />
regarding December 16, 2002<br />
Chairman’s Text for “solution” to<br />
Paragraph 6 of the Doha Declaration<br />
on TRIPS and Public Health, 19<br />
December 2002, available online<br />
here: http://www.msfaccess.org/<br />
content/letter-cptech-oxfam-msfand-hai-wto-delegates-regardingdecember-16-2002-chairmans-text<br />
(last accessed 16 November 2015).<br />
67 The EC proposal read: “This covers at<br />
least HIV/AIDS, malaria,<br />
tuberculosis, yellow fever, plague,<br />
cholera, meningococcal disease,<br />
African trypanosomiasis, dengue,<br />
influenza, leishmaniasis, hepatitis,<br />
leptospirosis, pertussis, poliomyelitis,<br />
schistosomiasis, typhoid fever,<br />
typhus measles, shigellosis,<br />
hemorrhagic fevers, and arboviruses.<br />
When requested by a Member, the<br />
World Heath Organization shall give<br />
its advice as to the occurrence on an<br />
importing Member, or the likelihood<br />
thereof, of any other public health<br />
problem.” This was a particularly<br />
cynical proposal since this list<br />
contained diseases for which a) there<br />
were no treatments available, or b) for<br />
which the treatment is off patent and<br />
c) for which little R&D was being<br />
carried out offering no prospect of<br />
any new medications soon. The list<br />
did not contain any diseases such as<br />
cancer or diabetes that would require<br />
access to patented treatments that<br />
actually existed. The quote, and more<br />
details from the meeting, can be<br />
found in a report by Mary Moran,<br />
“Reneging on Doha,” MSF Access<br />
Campaign, May 2003, https://www.<br />
msfaccess.org/sites/default/files/<br />
MSF_assets/Access/Docs/ACCESS_<br />
report_RenegingDoha_ENG_2003.<br />
pdf<br />
68 Cecilia Oh, “General Council<br />
“suspends” decision on TRIPS<br />
paragraph 6 solution (as informal<br />
consultations continue on<br />
“Chairman’s Understanding”), TWN<br />
Info Service on WTO Issues, 10 February<br />
155
Change language